WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced positive data demonstrating the utility of RXi’s self-delivering rxRNA™ (sd-rxRNA™) compounds, which are compounds that are delivered to cells without a delivery vehicle. The pharmacological data establish that in vivo administration of sd-rxRNA™ compounds result in preferential distribution to the liver in a mouse model, compared to the distribution of many other RNAi compounds that are rapidly filtered from the body via the kidneys.
